Cargando…

Bias in natriuretic peptide-guided heart failure trials: time to improve guideline adherence using alternative approaches

Treatment of patients with heart failure with reduced ejection fraction (HFrEF) with currently available therapies reduces morbidity and mortality. However, implementation of these therapies is a problem with only few patients achieving guideline-recommended maximal doses of therapy. In an effort to...

Descripción completa

Detalles Bibliográficos
Autores principales:	Stienen, Susan, Bhatt, Ankeet, Ferreira, João Pedro, Vaduganathan, Muthiah, Januzzi, James, Adams, Kirkwood, Tardif, Jean-Claude, Rossignol, Patrick, Zannad, Faiez
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7769782/ https://www.ncbi.nlm.nih.gov/pubmed/32783110 http://dx.doi.org/10.1007/s10741-020-10004-6

Ejemplares similares

Reply: Are We Missing Something in the Management of Acute Coronary Syndromes in COVID-19-Negative Patients?
por: Bhatt, Ankeet S., et al.
Publicado: (2020)

Innovation in Ambulatory Care of Heart Failure in the Era of Coronavirus Disease 2019
por: Leiva, Orly, et al.
Publicado: (2020)

Renin-angiotensin-aldosterone system and kidney interactions in heart failure
por: Ferreira, João Pedro, et al.
Publicado: (2019)

Clinical and Biomarker Predictors of Expanded Heart Failure Outcomes in Patients With Type 2 Diabetes Mellitus After a Recent Acute Coronary Syndrome: Insights From the EXAMINE Trial
por: Sharma, Abhinav, et al.
Publicado: (2020)

Fewer Hospitalizations for Acute Cardiovascular Conditions During the COVID-19 Pandemic
por: Bhatt, Ankeet S., et al.
Publicado: (2020)

Eplerenone in patients with myocardial infarction and “mid‐range” ejection fraction: An analysis from the EPHESUS trial
por: Ferreira, João Pedro, et al.
Publicado: (2019)

Accuracy of ICD-10 Diagnostic Codes to Identify COVID-19 Among Hospitalized Patients
por: Bhatt, Ankeet S., et al.
Publicado: (2021)

Influence of race in the estimation of glomerular filtration rate in patients with a high cardiovascular and renal risk
por: Ferreira, João Pedro, et al.
Publicado: (2021)

Alogliptin after acute coronary syndrome in patients with type 2 diabetes: a renal function stratified analysis of the EXAMINE trial
por: Ferreira, João Pedro, et al.
Publicado: (2020)

Body weight changes in patients with type 2 diabetes and a recent acute coronary syndrome: an analysis from the EXAMINE trial
por: Ferreira, João Pedro, et al.
Publicado: (2021)

Blood pressure reduction and anti‐hypertensive treatment choice: A post‐hoc analysis of the SPRINT trial
por: Ferreira, João Pedro, et al.
Publicado: (2021)

Manual Thrombectomy in Myocardial Infarction: Aspiring for Better
por: Vaduganathan, Muthiah, et al.
Publicado: (2015)

Daily home monitoring of potassium, creatinine, and estimated plasma volume in heart failure post‐discharge
por: Rossignol, Patrick, et al.
Publicado: (2020)

Natriuretic Peptide Testing in Primary Care
por: Rehman, Shafiq U, et al.
Publicado: (2008)

Investigating the Association Between Telemedicine Use and Timely Follow-Up Care After Acute Cardiovascular Hospital Encounters
por: Tang, Mitchell, et al.
Publicado: (2022)

Interplay between worsening kidney function and cardiovascular events in patients with type 2 diabetes: an analysis from the ACCORD trial
por: Ferreira, João Pedro, et al.
Publicado: (2021)

Potassium binders for the prevention of hyperkalaemia in heart failure patients: implementation issues and future developments
por: Zannad, Faiez, et al.
Publicado: (2019)

The Decline of the Experimental Paradigm During the COVID-19 Pandemic: A Template for the Future
por: Ferreira, João Pedro, et al.
Publicado: (2021)

Metabolic Syndrome and the Risk of Preclinical Heart Failure: Insights after 17 Years of Follow-Up from the STANISLAS Cohort
por: Sharma, Abhinav, et al.
Publicado: (2022)

Impact of natriuretic peptide polymorphisms on diastolic and metabolic function in a populational cohort: insights from the STANISLAS cohort
por: Xhaard, Constance, et al.
Publicado: (2021)

Clinical Outcomes in Patients With Heart Failure Hospitalized With COVID-19
por: Bhatt, Ankeet S., et al.
Publicado: (2021)

No influence of spironolactone on plasma concentrations of angiotensin-converting enzyme 2: Findings from the HOMAGE randomized trial
por: Ferreira, João Pedro, et al.
Publicado: (2021)

Eligibility for pharmacological therapies in heart failure with reduced ejection fraction: implications of the new Chronic Kidney Disease Epidemiology Collaboration creatinine equation for estimating glomerular filtration rate
por: Butt, Jawad H., et al.
Publicado: (2022)

The Importance of Amino-terminal pro-Brain Natriuretic Peptide Testing in Clinical Cardiology
por: Kimmenade, Van, et al.
Publicado: (2007)

Intima–Media Thickness Is Linearly and Continuously Associated With Systolic Blood Pressure in a Population‐Based Cohort (STANISLAS Cohort Study)
por: Ferreira, João Pedro, et al.
Publicado: (2016)

A comprehensive analysis of the effects of rivaroxaban on stroke or transient ischaemic attack in patients with heart failure, coronary artery disease, and sinus rhythm: the COMMANDER HF trial
por: Mehra, Mandeep R, et al.
Publicado: (2019)

Out-of-Pocket Costs for SGLT-2 (Sodium-Glucose Transport Protein-2) Inhibitors in the United States
por: Aggarwal, Rahul, et al.
Publicado: (2021)

Echocardiographic diastolic function evolution in patients with an anterior Q‐wave myocardial infarction: insights from the REVE‐2 study
por: Ferreira, João Pedro, et al.
Publicado: (2018)

Introduction
por: Zannad, Faiez
Publicado: (2019)

Un chercheur à succès est un chercheur qui a échoué et a recommencé
por: Zannad, Faiez
Publicado: (2022)

Neuromodulation in heart failure( )
por: Zannad, Faiez
Publicado: (2022)

Isolated diastolic hypertension and target organ damage: Findings from the STANISLAS cohort
por: Monzo, Luca, et al.
Publicado: (2021)

Circulating multimarker approach to identify patients with preclinical left ventricular remodelling and/or diastolic dysfunction
por: Huttin, Olivier, et al.
Publicado: (2021)

Uric acid and sodium-glucose cotransporter-2 inhibition with empagliflozin in heart failure with reduced ejection fraction: the EMPEROR-reduced trial( )
por: Doehner, Wolfram, et al.
Publicado: (2022)

Concentration‐dependent clinical and prognostic importance of high‐sensitivity cardiac troponin T in heart failure and a reduced ejection fraction and the influence of empagliflozin: the EMPEROR‐Reduced trial
por: Packer, Milton, et al.
Publicado: (2021)

Effect of empagliflozin on circulating proteomics in heart failure: mechanistic insights into the EMPEROR programme
por: Zannad, Faiez, et al.
Publicado: (2022)

Empagliflozin for Patients With Presumed Resistant Hypertension: A Post Hoc Analysis of the EMPA-REG OUTCOME Trial
por: Ferreira, João Pedro, et al.
Publicado: (2020)

A rationale for dedicated trials of combination therapy in heart failure
por: Blumer, Vanessa, et al.
Publicado: (2022)

Closer to FREEDOM From Uncertainty
por: Vaduganathan, Muthiah, et al.
Publicado: (2023)

Randomised controlled trials and alternative therapy
por: Krishna, Sreedhar K., et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_suaaq66di2dbc3p3ahn9ivsq6d